BACKGROUND: Metabolic diseases are frequently observed in HIV-infected persons and, as the risk of contracting these diseases is age-related, their prevalence will increase in the future as a consequence of the benefits of antiretroviral therapy (ART). SUMMARY OF GUIDELINES: All HIV-infected persons should be screened at regular intervals for a history of metabolic disease, dyslipidaemia, diabetes mellitus, hypertension and alteration of body composition; cardiovascular risk and renal function should also be assessed. Efforts to prevent cardiovascular disease will vary in intensity depending on an individual's absolute risk of ischaemic heart disease and should be comprehensive in nature. Lifestyle interventions should focus on counselling to stop smoking, modify diet and take regular exercise. A healthy diet, exercise and maintaining normal body weight tend to reduce dyslipidaemia; if not effective, a change of ART should be considered, followed by use of lipid-lowering medication in high-risk patients. A pre-emptive switch from thymidine analogues is recommended to reduce the risk of development or progression of lipoatrophy. Intra-abdominal fat accumulation is best managed by exercise and diet. Prevention and management of type 2 diabetes mellitus and hypertension follow guidelines used in the general population. When using medical interventions to prevent and/or treat metabolic disease(s), impairment of the efficacy of ART should be avoided by considering the possibility of pharmacokinetic interactions and compromised adherence. Specialists in HIV and specialists in metabolic diseases should consult each other, in particular in difficult-to-treat cases. CONCLUSION: Multiple and relatively simple approaches exist to prevent metabolic diseases in HIV-infected persons; priority should be given to patients at high risk of contracting these diseases.

European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV / J. D., Lundgren; M., Battegay; G., Behrens; S., De Wit; Guaraldi, Giovanni; C., Katlama; E., Martinez; D., Nair; W. G., Powderly; P., Reiss; J., Sutinen; A., Vigano; EACS Executive, Committee. - In: HIV MEDICINE. - ISSN 1464-2662. - STAMPA. - 2008 Feb;9(2):(2008), pp. 72-81. [10.1111/j.1468-1293.2007.00534.x]

European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV.

GUARALDI, Giovanni;
2008

Abstract

BACKGROUND: Metabolic diseases are frequently observed in HIV-infected persons and, as the risk of contracting these diseases is age-related, their prevalence will increase in the future as a consequence of the benefits of antiretroviral therapy (ART). SUMMARY OF GUIDELINES: All HIV-infected persons should be screened at regular intervals for a history of metabolic disease, dyslipidaemia, diabetes mellitus, hypertension and alteration of body composition; cardiovascular risk and renal function should also be assessed. Efforts to prevent cardiovascular disease will vary in intensity depending on an individual's absolute risk of ischaemic heart disease and should be comprehensive in nature. Lifestyle interventions should focus on counselling to stop smoking, modify diet and take regular exercise. A healthy diet, exercise and maintaining normal body weight tend to reduce dyslipidaemia; if not effective, a change of ART should be considered, followed by use of lipid-lowering medication in high-risk patients. A pre-emptive switch from thymidine analogues is recommended to reduce the risk of development or progression of lipoatrophy. Intra-abdominal fat accumulation is best managed by exercise and diet. Prevention and management of type 2 diabetes mellitus and hypertension follow guidelines used in the general population. When using medical interventions to prevent and/or treat metabolic disease(s), impairment of the efficacy of ART should be avoided by considering the possibility of pharmacokinetic interactions and compromised adherence. Specialists in HIV and specialists in metabolic diseases should consult each other, in particular in difficult-to-treat cases. CONCLUSION: Multiple and relatively simple approaches exist to prevent metabolic diseases in HIV-infected persons; priority should be given to patients at high risk of contracting these diseases.
2008
2008 Feb;9(2)
72
81
European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV / J. D., Lundgren; M., Battegay; G., Behrens; S., De Wit; Guaraldi, Giovanni; C., Katlama; E., Martinez; D., Nair; W. G., Powderly; P., Reiss; J., Sutinen; A., Vigano; EACS Executive, Committee. - In: HIV MEDICINE. - ISSN 1464-2662. - STAMPA. - 2008 Feb;9(2):(2008), pp. 72-81. [10.1111/j.1468-1293.2007.00534.x]
J. D., Lundgren; M., Battegay; G., Behrens; S., De Wit; Guaraldi, Giovanni; C., Katlama; E., Martinez; D., Nair; W. G., Powderly; P., Reiss; J., Sutinen; A., Vigano; EACS Executive, Committee
File in questo prodotto:
File Dimensione Formato  
j.1468-1293.2007.00534.x.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 157.35 kB
Formato Adobe PDF
157.35 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/591357
Citazioni
  • ???jsp.display-item.citation.pmc??? 58
  • Scopus 188
  • ???jsp.display-item.citation.isi??? 153
social impact